Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Ampronix
GLOBETECH PUBLISHING LLC

Benefits Weighed of Targeted Clot Removal Based on Brain Status

By Medimaging International staff writers
Posted on 19 Feb 2013
The use of cutting-edge imaging technology just after the onset of acute stroke failed to identify a subgroup of patients who could benefit from a clot-removal procedure.

The randomized, controlled trial known as Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) was funded by the US National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (Bethesda, MD, USA), and the findings were published online February 12, 2013, in the New England Journal of Medicine (NEJM).

In patients with ischemic stroke (caused by a blockage in an artery), brain cells deprived of blood die within minutes to hours. Quickly opening the artery can stop brain cell death. Intravenous tissue plasminogen activator (t-PA), an agent that dissolves clots has been shown to improve outcomes in these stroke patients. However, intravenous t-PA is not effective in many patients with large clots blocking the major brain arteries that cause the most damaging strokes. MR RESCUE scientists evaluated an invasive clot removal approach devised to remove clots from these large arteries. Patients in the study were enrolled at 22 centers in the United States within approximately 5.5 hours of their stroke onset. Their ability to function independently was assessed at 90 days.

All MR-RESCUE patients underwent emergency computed tomography (CT) or magnetic resonance (MRI) perfusion imaging to find the brain areas with decreased blood flow, as well as regions that could not be salvaged.

The investigators theorized that patients in whom the MRI scan suggested that less than 70% of the brain with decreased blood flow had already died would benefit from the clot-removal procedures. Based on the imaging findings, the 118 study patients were randomly assigned to receive a clot-removal procedure within eight hours of symptom onset (64 patients) or conventional therapy (54 patients) according to medical protocols. The procedure involves threading a customized catheter through an artery in the groin up to the site of a clot in a brain artery, then removing the blockage.

“Despite a lack of evidence showing that these clot-removal devices improve outcomes, they are already widely used in patients who are not able to get to the hospital in time to receive t-PA,” said Walter J. Koroshetz, MD, deputy director of NINDS. “Though some patients have had dramatic improvements with clot removal, it has not been shown effective in this or another larger study, the Interventional Management of Stroke [IMS III], which was halted early because it did not find the procedure to be of significant benefit.”

“The majority of patients were not eligible to receive intravenous t-PA, the only drug approved by the Food and Drug Administration for the treatment of stroke, because they arrived at the hospital too late for t-PA to be effective,” said one of the lead investigators, Chelsea Kidwell, MD, from Georgetown University Medical Center (Washington DC, USA).

The patients with the presumed optimistic imaging findings had the same level of disability at 90 days whether or not they had undergone the clot-removal procedure or had received standard therapy. The researchers hypothesized that the lack of a treatment effect may reflect the fact that these patients had enough blood flow to the brain from secondary sources to support the brain tissue until spontaneous reperfusion occurred. Patients without the favorable imaging findings did not benefit from the clot-removal procedure.

However, the MR RESCUE results were not consistent with the conclusions of a separate NINDS-funded observational study called DEFUSE-2 that suggested that a slightly different brain imaging approach could predict patients who benefited from the clot-removal procedure.

In addition to other imaging modalities, “it’s possible that newer intra-arterial devices that were not available when the study started could improve functional outcomes,” said Scott Janis, PhD, program director, NINDS. “But an important message from MR RESCUE is that those newer devices still need to go head to head with standard therapy.”

“Advances in neuroimaging are promising and may someday help to identify who will benefit from a device-based approach. But the MR RESCUE results show that more work needs to be done,” Dr. Koroshetz concluded.

Related Links:
US National Institute of Neurological Disorders and Stroke
Georgetown University Medical Center



Channels

Radiography

view channel
Image: Fujifilm\'s Aspire Cristalle (Photo courtesy of Business Wire).

Diagnostic Imaging Solutions Provider Submits Mammography Upgrade for FDA Approval

A leading provider of medical informatics solutions and diagnostic imaging products has submitted the first of several modules of its Digital Breast Tomosynthesis (DBT) upgrade for its mammography system,... Read more

Ultrasound

view channel

New Ultrasound System Enhances Patient Care and User Experience

A new ultrasound system with innovative specialized transducers and improved image quality, intended for general imaging, women’s health, and shared service applications, has been announced. The system features improved accuracy, performance, assessment tools, advanced automation, and an enhanced user experience.... Read more

Nuclear medicine

view channel

Clinical Study Shows Added Value of Amyloid PET Imaging in the Diagnosis and Treatment of Dementia

Early-onset dementia patients could benefit from a new PET imaging agent developed by a major medical imaging vendor. The results of a clinical study showing the effectiveness of the amyloid PET imaging agent were presented at the Alzheimer’s Association International Conference (AAIC 2015) in Washington DC (USA).... Read more

General/Advanced Imaging

view channel
Image: Illustration of a new technique using Optical Coherence Tomography that could help surgeons differentiate a human brain tumor, red, from surrounding noncancerous tissue, green (Photo courtesy of  Carmen Kut, Jordina Rincon-Torroella, Xingde Li and Alfredo Quinones-Hinojosa/Johns Hopkins Medicine).

Imaging Technique Helps Safer and More Effective Removal of Brain Tumors

Researchers at the Johns Hopkins University have demonstrated a new imaging technology that could enable neurosurgeons to better differentiate between healthy and cancerous brain tissue and perform safer... Read more

Imaging IT

view channel
Image: The Arbor Solution M2150 medical workstation with 21.5\

Multifunction Workstation Screen Meets Critical Certification Standards for Medical Environments

A medical imaging equipment vendor has unveiled a new workstation with a 54.61 cm true flat screen designed for operating rooms, clinical stations, and Picture Archiving and Communications Systems (PACS).... Read more

Industry News

view channel

Guerbet Aims for Global Medical Imaging Leadership by Acquisition of Mallinckrodt’s CMDS Business

Guerbet (Paris, France) has announced a definitive agreement for the acquisition of the Contrast Media and Delivery Systems (CMDS) business of pharmaceutical giant Mallinckrodt (Chesterfield, Derbyshire, UK). The acquisition gave Guerbet and the CMDS unit combined pro-forma sales of nearly EUR 800 million in 2014, a... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.